evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

537 questions · 558 findings · 32 reviews · Gut

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 134 · 24%GRADE not reported 11 · 2%Very low 143 · 25.6%Low 138 · 24.7%Moderate 106 · 19%High 26 · 4.7%

Infliximab 5 mg/kg vs CT‐P13 biosimilar 5 mg/kg

Clinical response defined by reduction of CDAI score by ≥ 100 at week 6 · Patients with active Crohn's disease

Infliximab 5 mg/kg showed no clear difference in clinical response defined by reduction of CDAI score by ≥ 100 at… compared with CT‐P13 biosimilar 5 mg/kg (low certainty).

1 finding from 1 review

Infliximab 5–10 mg/kg vs placebo

Withdrawals due to adverse events · Patients with active Crohn's disease

The review found no eligible studies for this question.

2 findings from 1 review

Infliximab 5–10 mg/kg vs placebo

Clinical remission defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5–10 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with placebo (very low certainty).

1 finding from 1 review

Infliximab 5–10 mg/kg vs placebo

Clinical response defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5–10 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with placebo (very low certainty).

1 finding from 1 review

Infliximab 5 mg/kg and purine analogues vs purine analogues

Clinical response as defined by the studies at week 26 · Patients with active Crohn's disease

Infliximab 5 mg/kg and purine analogues probably leads to higher clinical response as defined by the studies at week 26 compared with purine analogues alone (moderate certainty).

1 finding from 1 review

Fecal microbiota transplantation vs control

Serious adverse events with use of FMT for induction of remission in UC (RR > 1 favors control) · people with active UC

It is very uncertain whether fecal microbiota transplantation changes serious adverse events with use of FMT for induction of remission in… compared with control (very low certainty).

1 finding from 1 review

Fecal microbiota transplantation vs control

Any adverse events with use of FMT for induction of remission in UC (RR > 1 favors control) · people with active UC

Fecal microbiota transplantation showed no clear difference in any adverse events with use of FMT for induction of remission in UC… compared with control (low certainty).

1 finding from 1 review